Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | LTA4H | P09960 | 6/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | ADRA1D | P25100 | 3/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.41 |
| ▸ | ADRA1B | P35368 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.38 |
| ▸ | NR1D1 | P20393 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1019545 | 0.91 | KDM4E (0.41) | KDM4ELTA4HHPGDADRA1DADRA1A | |
| SCHEMBL1018053 | 0.82 | LTA4H (0.40) | KDM4ELTA4HHPGDLMNASMN1; SMN2 | |
| SCHEMBL1879135 | 0.82 | CA2 (0.40) | KDM4ELTA4HHPGDLMNASMN1; SMN2 | |
| SCHEMBL22204407 | 0.74 | KDM4E (0.46) | KDM4ELTA4HADRA1AL3MBTL1 | |
| SCHEMBL1019554 | 0.74 | LTA4H (0.34) | LTA4HHPGDLMNASMN1; SMN2MEN1 | |
| SCHEMBL1018752 | 0.73 | CA2 (0.39) | LTA4HHPGDLMNASMN1; SMN2MEN1 | |
| SCHEMBL8184470 | 0.73 | CA2 (0.43) | HPGDSMN1; SMN2ALOX5NR1D1CA2 | |
| SCHEMBL6974656 | 0.70 | ADRA1A (0.47) | HPGDADRA1DADRA1AADRA1BCA2 | |
| SCHEMBL1021052 | 0.70 | ADRA1A (0.47) | HPGDADRA1DADRA1AADRA1BCA2 | |
| SCHEMBL1019856 | 0.70 | ADRA1D (0.60) | HPGDADRA1DADRA1AADRA1BCA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2271634-B1 | MODULATORS OF DOPAMINE NEUROTRANSMISSION | INTEGRATIVE RES LAB SWEDEN AB (SE) | 2014-02-12 | — | — | EP | disclosed |
| US-8524766-B2 | Modulators of dopamine neurotransmission | NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE (DK) | 2013-09-03 | — | — | US | disclosed |
| US-20110105461-A1 | MODULATORS OF DOPAMINE NEUROTRANSMISSION | NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE (DK) | 2011-05-05 | — | — | US | disclosed |
| EP-2271634-A1 | MODULATORS OF DOPAMINE NEUROTRANSMISSION | NSAB, Filial af NeuroSearch Sweden AB, Sverige (DK) | 2011-01-12 | — | — | EP | disclosed |
| WO-2009133107-A1 | MODULATORS OF DOPAMINE NEUROTRANSMISSION | NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE (DK) | 2009-11-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105461-A1 | MODULATORS OF DOPAMINE NEUROTRANSMISSION | DBH, SLC18A2, SLC6A3 | KDM4E 1570/4885LTA4H 1989/4885HPGD 494/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.